GlassScriptPhysician profile
Tanuj Bhatnagar
NPI 1205918679
$7,002.45
in general payments reported to CMS, 2019-2025
28 companies · $1,276 in 2025
The $1,276 reported for 2025 was more than what 75% of Sleep Medicine (Internal Medicine) providers received nationally (typical 2025 total: $447).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,237 · 2020: $389 · 2021: $1,072 · 2022: $1,137 · 2023: $945 · 2024: $946 · 2025: $1,276.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,167.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,906.58 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,921.92 | 2019-2025 | Breztri, Tezspire, Airsupra |
| Mylan Specialty L.P. | $452.94 | 2020-2024 | Yupelri |
| Mallinckrodt Hospital Products INC. | $202.93 | 2021-2025 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.22 | 2020-2025 | Jascayd |
| Edwards Lifesciences Corporation | $144.58 | 2019-2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Regeneron Healthcare Solutions, INC. | $138.99 | 2019-2025 | Dupixent |
| Philips North America LLC | $134.39 | 2019-2020 | |
| Verona Pharma, INC. | $126.11 | 2025 | Ohtuvayre |
| Viatris Specialty LLC | $103.48 | 2025 | Yupelri |
| Inspire Medical Systems, INC. | $93.32 | 2024-2025 | Inspire |
| Teva Pharmaceuticals USA, INC. | $82.51 | 2021-2022 | |
| Electromed, INC. | $81.82 | 2021-2025 | Smartvest |
| Merck Sharp & Dohme LLC | $76.32 | 2020-2023 | Belsomra |
| Amgen INC. | $59.68 | 2023-2025 | Tezspire |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $54.71 | 2021 | |
| Insmed, INC. | $46.73 | 2021-2025 | Brinsupri, Arikayce |
| Genzyme Corporation | $30.55 | 2023 | |
| Sunovion Pharmaceuticals INC. | $30.00 | 2019 | |
| Mallinckrodt Enterprises LLC | $27.27 | 2019 | |
| Boston Scientific Corporation | $23.33 | 2019 | |
| Pulmonx Corporation | $22.13 | 2025 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Actelion Pharmaceuticals US, INC. | $20.64 | 2025 | Opsynvi |
| Lilly USA, LLC | $18.81 | 2025 | Zepbound |
| Harmony Biosciences LLC | $15.97 | 2025 | |
| Sanofi-Aventis U.S. LLC | $15.00 | 2019 | |
| 3b Medical, INC. | $14.52 | 2025 | Luna |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tanuj Bhatnagar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.